DUL:ETR
Alnylam Pharmaceuticals, Inc.
209,10 €
arrow_upward
+1,26%(+2,60) 1D
12. lis, 13:17:55 GMT+2 · EUR
search
Svi simboli
| Simbol | Cijena | Promjena | Postotna promjena |
|---|
insights_autoGeneriranje najvažnijih uvida za DUL...
Otvori
209,10 €
Najviša
209,10 €
Najniža
209,10 €
Trž. kap.
30,76 mlr.
Prosj. kol.
40,00
Količina
10,00
52-tjed. najviša
417,40 €
52-tjed. najniža
177,10 €
Broj djelatnika
2 tis.
Otvori
209,10 €
Najviša
209,10 €
Najniža
209,10 €
Trž. kap.
30,76 mlr.
Prosj. kol.
40,00
Količina
10,00
52-tjed. najviša
417,40 €
52-tjed. najniža
177,10 €
Broj djelatnika
2 tis.
Vijesti
Iz web-izvora i od partnera za vijesti
Investing.com
·
prije 1 dan
Alnylam EVP Bryan Supran sells $398,855 in shares
Investing.com Nigeria
·
prije 1 dan
Form 4 Alnylam Pharmaceuticals Inc For: 11 October By Investing.com
Simply Wall Street
·
prije 1 dan
How Securities Fraud Scrutiny Will Impact Alnylam Stock Investors
Yahoo Finance
·
prije 2 dana
Alnylam vs. Ionis: Here's the Better Bad-News Buy
Profil
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. Wikipedia
Alnylam Pharmaceuticals, Inc. – informacije
Glavni izvršni direktor-
Zaposlenici2,5 tis.
Osnovano14. lip 2002.
Sjedište-
Sektor-
Web-lokacijaalnylam.com